Abstract:Background:Antibiotic resistance (ABR) is one of the biggest threats to global health. Infections by ESKAPE (Enterococcus, S. aureus, K. pneumoniae, A. baumannii, P. aeruginosa, and E. coli) organisms are the leading cause of healthcare-acquired infections worldwide. ABR in ESKAPE organisms is usually associated with significant higher morbidity, mortality, as well as economic burden. Directing attention towards the ESKAPE organisms can help us to better combat the wide challenge of ABR, especially multi-drug resistance (MDR).Objective:This study aims to systematically review and evaluate the evidence of the economic consequences of ABR or MDR ESKAPE organisms compared with susceptible cases or control patients without infection/colonization in order to determine the impact of ABR on economic burden.Methods:Both English-language databases and Chinese-language databases up to 16 January, 2019 were searched to identify relevant studies assessing the economic burden of ABR. Studies reported hospital costs (charges) or antibiotic cost during the entire hospitalization and during the period before/after culture among patients with ABR or MDR ESKAPE organisms were included. The costs were converted into 2015 United States Dollars. Disagreements were resolved by a third reviewer.Results:Of 13,693 studies identified, 83 eligible studies were included in our review. The most studied organism was S. aureus, followed by Enterococcus, A. baumannii, E. coli, E. coli or/and K. pneumoniae, P. aeruginosa, and K. pneumoniae. There were 71 studies on total hospital cost or charge, 12 on antibiotic cost, 11 on hospital cost or charge after culture, 4 on ICU cost, 2 on hospital cost or charge before culture, and 2 on total direct and indirect cost. In general, ABR or MDR ESKAPE organisms are significantly associated with higher economic burden than those with susceptible organisms or those without infection or colonization. Nonetheless, there were no differences in a few studies between the two groups on total hospital cost or charge (16 studies), antibiotic cost (one study), hospital cost before culture (one study), hospital cost after culture (one study). Even, one reported that costs associated with MSSA infection were higher than the costs for similar MRSA cases.Conclusions:ABR in ESKAPE organisms is not always, but usually, associated with significantly higher economic burden. The results without significant differences may lack statistical power to detect a significant association. In addition, study design which controls for severity of illness and same empirical antibiotic therapy in the two groups would be expected to bias the study towards a similar, even negative result. The review also highlights key areas where further research is needed.

Direct economic burden and outcomes among patients with carbapenem-resistant acinetobacter baumannii infection or colonization

PMU28 CLINICAL AND ECONOMIC OUTCOMES OF CARBAPENEM-RESISTANT GRAM-NEGATIVE ORGANISMS: A MULTICENTER STUDY IN CHINA

The Difference in Medical Costs Between Carbapenem-Resistant Acinetobacter Baumannii and Non-Resistant Groups: a Case Study from a Hospital in Zhejiang Province, China

Clinical and Economic Burden of Carbapenem-Resistant Infection or Colonization Caused by Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii: A Multicenter Study in China

PMU82 EFFECT OF CARBAPENEM RESISTANCE ON TOTAL HOSPITALIZATION COSTS AMONG INPATIENTS WITH PSEUDOMONAS AERUGINOSA: A MULTICENTER STUDY IN CHINA

Prospective multi-center evaluation on risk factors, clinical characteristics and outcomes due to carbapenem resistance in Acinetobacter baumannii complex bacteraemia: experience from the Chinese Antimicrobial Resistance Surveillance of Nosocomial Infections (CARES) Network.

Risk Factors and Molecular Epidemiology of Complicated Intra-Abdominal Infections With Carbapenem-Resistant <i>Enterobacteriaceae</i>: A Multicenter Study in China

Risk Factors and Mortality of Patients with Nosocomial Carbapenem-Resistant Acinetobacter Baumannii Pneumonia.

Assessment of Effective Antimicrobial Regimens and Mortality-Related Risk Factors for Bloodstream Infections Caused by Carbapenem-Resistant Acinetobacter Baumannii.

Epidemiological characteristics of carbapenem-resistant Acinetobacter baumannii hospital-associated infection in ICU patients of general hospitals

Impact of Carbapenem-Resistant Acinetobacter Baumannii Infections on Acute Pancreatitis Patients

In-hospital Medical Costs of Infections Caused by Carbapenem-resistant Klebsiella Pneumoniae.

The Clinical and Economic Impact of Antibiotic Resistance in China: A Systematic Review and Meta-Analysis

Risk factor for intestinal carriage of carbapenem-resistant Acinetobacter baumannii and the impact on subsequent infection among patients in an intensive care unit: an observational study

Risk factors and prognosis of patients with bloodstream infection due to carbapenem-resistant Acinetobacter baumannii

Clinical and Economic Impact of Third-Generation Cephalosporin-Resistant Infection or Colonization Caused by Escherichia Coli and Klebsiella Pneumoniae: A Multicenter Study in China

Retrospective Comparative Analysis of Risk Factors and Outcomes in Patients with Carbapenem- Resistant Acinetobacter Baumannii Bloodstream Infections: Cefoperazone-Sulbactam Associated with Resistance and Tigecycline Increased the Mortality

Socioeconomic burden of bloodstream infections caused by carbapenem-resistant and carbapenem-susceptible Pseudomonas aeruginosa in China

Economic Burden of Antibiotic Resistance in ESKAPE Organisms: a Systematic Review

OP115 Effect of Multiple Drug Resistance on Costs for Patients with Intra-Abdominal Infections in China

Risk factors and medical costs for healthcare-associated carbapenem-resistant Escherichia coli infection among hospitalized patients in a Chinese teaching hospital